Logo image of AVR

ANTERIS TECHNOLOGIES GLOBAL (AVR) Stock Fundamental Analysis

USA - NASDAQ:AVR - US03675P1021 - Common Stock

5.59 USD
-0.29 (-4.93%)
Last: 10/23/2025, 8:00:01 PM
5.35 USD
-0.24 (-4.29%)
After Hours: 10/23/2025, 8:00:01 PM
Fundamental Rating

2

We assign a fundamental rating of 2 out of 10 to AVR. AVR was compared to 190 industry peers in the Health Care Equipment & Supplies industry. The financial health of AVR is average, but there are quite some concerns on its profitability. AVR has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

0

1. Profitability

1.1 Basic Checks

In the past year AVR has reported negative net income.
AVR Yearly Net Income VS EBIT VS OCF VS FCFAVR Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2022 2023 2024 -20M -40M -60M

1.2 Ratios

With a Return On Assets value of -210.47%, AVR is not doing good in the industry: 93.16% of the companies in the same industry are doing better.
AVR has a worse Return On Equity (-343.90%) than 76.84% of its industry peers.
Industry RankSector Rank
ROA -210.47%
ROE -343.9%
ROIC N/A
ROA(3y)-145.5%
ROA(5y)N/A
ROE(3y)-232.78%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
AVR Yearly ROA, ROE, ROICAVR Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2022 2023 2024 -100 -200 -300

1.3 Margins

AVR's Gross Margin of 59.40% is in line compared to the rest of the industry. AVR outperforms 58.42% of its industry peers.
The Profit Margin and Operating Margin are not available for AVR so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 59.4%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
AVR Yearly Profit, Operating, Gross MarginsAVR Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2022 2023 2024 0 -500 -1K -1.5K -2K -2.5K

4

2. Health

2.1 Basic Checks

AVR does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for AVR remains at a similar level compared to 1 year ago.
Compared to 1 year ago, AVR has an improved debt to assets ratio.
AVR Yearly Shares OutstandingAVR Yearly Shares OutstandingYearly Shares Outstanding 2022 2023 2024 10M 20M 30M
AVR Yearly Total Debt VS Total AssetsAVR Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2022 2023 2024 20M 40M 60M 80M

2.2 Solvency

Based on the Altman-Z score of -9.77, we must say that AVR is in the distress zone and has some risk of bankruptcy.
AVR has a Altman-Z score of -9.77. This is in the lower half of the industry: AVR underperforms 79.47% of its industry peers.
AVR has a Debt/Equity ratio of 0.00. This is a healthy value indicating a solid balance between debt and equity.
AVR's Debt to Equity ratio of 0.00 is fine compared to the rest of the industry. AVR outperforms 73.68% of its industry peers.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -9.77
ROIC/WACCN/A
WACC8.6%
AVR Yearly LT Debt VS Equity VS FCFAVR Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2022 2023 2024 0 20M -20M 40M -40M 60M -60M

2.3 Liquidity

A Current Ratio of 2.41 indicates that AVR has no problem at all paying its short term obligations.
AVR has a Current ratio of 2.41. This is comparable to the rest of the industry: AVR outperforms 47.89% of its industry peers.
AVR has a Quick Ratio of 2.38. This indicates that AVR is financially healthy and has no problem in meeting its short term obligations.
AVR has a Quick ratio of 2.38. This is comparable to the rest of the industry: AVR outperforms 59.47% of its industry peers.
Industry RankSector Rank
Current Ratio 2.41
Quick Ratio 2.38
AVR Yearly Current Assets VS Current LiabilitesAVR Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2022 2023 2024 20M 40M 60M

3

3. Growth

3.1 Past

AVR shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -65.77%.
Looking at the last year, AVR shows a decrease in Revenue. The Revenue has decreased by -1.16% in the last year.
EPS 1Y (TTM)-65.77%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%N/A
Revenue 1Y (TTM)-1.16%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

AVR is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 11.75% yearly.
Based on estimates for the next years, AVR will show a very strong growth in Revenue. The Revenue will grow by 36.88% on average per year.
EPS Next Y19.52%
EPS Next 2Y14.75%
EPS Next 3Y11.75%
EPS Next 5YN/A
Revenue Next Year5.99%
Revenue Next 2Y93.05%
Revenue Next 3Y36.88%
Revenue Next 5YN/A

3.3 Evolution

AVR Yearly Revenue VS EstimatesAVR Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2022 2023 2024 2025 2026 2027 2M 4M 6M 8M 10M
AVR Yearly EPS VS EstimatesAVR Yearly EPS VS EstimatesYearly EPS VS Estimates 2024 2025 2026 2027 -0.5 -1 -1.5 -2 -2.5

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for AVR. In the last year negative earnings were reported.
Also next year AVR is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
AVR Price Earnings VS Forward Price EarningsAVR Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
AVR Per share dataAVR EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -1 -2

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y14.75%
EPS Next 3Y11.75%

0

5. Dividend

5.1 Amount

No dividends for AVR!.
Industry RankSector Rank
Dividend Yield N/A

ANTERIS TECHNOLOGIES GLOBAL

NASDAQ:AVR (10/23/2025, 8:00:01 PM)

After market: 5.35 -0.24 (-4.29%)

5.59

-0.29 (-4.93%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)08-11 2025-08-11/amc
Earnings (Next)12-09 2025-12-09
Inst Owners42.86%
Inst Owner Change0%
Ins Owners0.21%
Ins Owner Change0%
Market Cap201.58M
Revenue(TTM)2.48M
Net Income(TTM)-83931900
Analysts80
Price Target16.83 (201.07%)
Short Float %2.88%
Short Ratio5.73
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-17.64%
Min EPS beat(2)-27.6%
Max EPS beat(2)-7.67%
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)2
Avg Revenue beat(2)20.17%
Min Revenue beat(2)17.96%
Max Revenue beat(2)22.38%
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-9.87%
EPS NY rev (1m)0%
EPS NY rev (3m)-9.64%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-52%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-13.08%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 81.31
P/FCF N/A
P/OCF N/A
P/B 8.26
P/tB 8.29
EV/EBITDA N/A
EPS(TTM)-2.33
EYN/A
EPS(NY)-2.01
Fwd EYN/A
FCF(TTM)N/A
FCFYN/A
OCF(TTM)N/A
OCFYN/A
SpS0.07
BVpS0.68
TBVpS0.67
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -210.47%
ROE -343.9%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 59.4%
FCFM N/A
ROA(3y)-145.5%
ROA(5y)N/A
ROE(3y)-232.78%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-ScoreN/A
Asset Turnover0.06
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.41
Quick Ratio 2.38
Altman-Z -9.77
F-ScoreN/A
WACC8.6%
ROIC/WACCN/A
Cap/Depr(3y)191.13%
Cap/Depr(5y)N/A
Cap/Sales(3y)74.66%
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-65.77%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%N/A
EPS Next Y19.52%
EPS Next 2Y14.75%
EPS Next 3Y11.75%
EPS Next 5YN/A
Revenue 1Y (TTM)-1.16%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next Year5.99%
Revenue Next 2Y93.05%
Revenue Next 3Y36.88%
Revenue Next 5YN/A
EBIT growth 1Y-64.9%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-11.82%
EBIT Next 3Y-0.71%
EBIT Next 5YN/A
FCF growth 1Y-71.56%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-76.84%
OCF growth 3YN/A
OCF growth 5YN/A